Company Overview: ALXN

Upcoming Projects (ALXN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ALXN)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (ALXN)

Evaluating the Market Potential of Eculizumab As A Treatment For Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ticker: ALXN
Execute By: Nov 15, 2019
Discussing the potential for US FDA approval for Soliris (Eculizumab) in treating Refractory generalized myasthenia gravis before FDA decision expected Oct. 23, 2017
Ticker: ALXN
Execute By: Oct 20, 2017

Upcoming & Overdue Catalysts (ALXN)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ALXN)

Alexion's (ALXN) ALXN1210 in atypical Hemolytic Uremic Syndrome (aHUS) PDUFA data under priority review October 19, 2019
Ticker: ALXN
Occurred on: Oct 18, 2019
Alexion Pharmaceuticals (ALXN) Eculizumab Phase 3 data for relapsing NMOSD in PREVENT trial due mid 2018
Ticker: ALXN
Occurred on: Sep 24, 2018
Alexion (ALXN) Announces Results From Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Ticker: ALXN
Occurred on: Mar 15, 2018
The FDA set a Prescription Drug User Fee Act (PDUFA) date of October 23, 2017 for Soliris (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG)
Ticker: ALXN
Occurred on: Oct 23, 2017
Enrollment for ALXN-1210 Phase 3 pediatric study on atypical hemolytic uremic syndrome (aHUS) to initiate in second quarter of 2017
Ticker: ALXN
Occurred on: Jul 27, 2017
FDA Accepted SBLA Filing Of Soliris (Eculizumab) As A Potential Treatment For Patients With Refractory Generalized Myasthenia Gravis (GMG)
Ticker: ALXN
Occurred on: Mar 08, 2017
Alexion (ALXN) Announces Submission of U.S and EU Regulatory Applications for Soliris (Eculizumab) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
Ticker: ALXN
Occurred on: Jan 09, 2017
Alexion (ALXN) Expects EU and FDA Regulatory Submissions for Soliris in Refractory Myasthenia Gravis in Q1 2017
Ticker: ALXN
Occurred on: Jan 09, 2017
Alexion (ALXN) Plans to Initiate a Phase 3 Trial of ALXN1210 in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS) in 2017
Ticker: ALXN
Occurred on: Jan 06, 2017
Enrollment for ALXN1210 Phase 3 SWITCH study on Paroxysmal nocturnal hemoglobinuria (PNH) set to begin in Q2 of 2017
Ticker: ALXN
Occurred on: Jan 06, 2017
Alexion's (ALXN) ALXN1210 Granted Orphan Drug Designation by FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Ticker: ALXN
Occurred on: Jan 06, 2017
Alexion (ALXN) Presents Top-Line Phase 2/3 PROTECT Data Evaluating Eculizumab (Soliris®) For The Prevention Of Delayed Graft Function (DGF) After Kidney Transplantation
Ticker: ALXN
Occurred on: Dec 21, 2016
Alexion (ALXN) Presents Data from Phase 1/2 Dose-Escalation Study of ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Ticker: ALXN
Occurred on: Dec 04, 2016
Alexion (ALXN) Initiates Dosing in Phase I Study Evaluating ALXN1210 Administered Subcutaneously to Healthy Volunteers
Ticker: ALXN
Occurred on: Oct 27, 2016
Alexion (ALXN) To Begin Enrolling Patients This Quarter in Simultaneous Phase 3 Registration Trials for ALXN1210 in Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
Ticker: ALXN
Occurred on: Oct 27, 2016
Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)
Ticker: ALXN
Occurred on: Jul 14, 2016
New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Presented at ICNMD Annual Congress
Ticker: ALXN
Occurred on: Jul 07, 2016
Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH
Ticker: ALXN
Occurred on: Jun 10, 2016
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
Ticker: ALXN
Occurred on: Jun 06, 2016
European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Ticker: ALXN
Occurred on: Jun 01, 2016

Strategic Initiatives (ALXN)

AstraZeneca (AZN) receives US clearance of proposed acquisition of Alexion (ALXN)
Tickers: AZN, ALXN
Announcement Date: Apr 16, 2021
AstraZeneca (AZN) to acquire Alexion (ALXN), building its rare disease portfolio
Tickers: AZN, ALXN
Announcement Date: Dec 12, 2020
U.S. Federal Trade Commission has granted early termination of the waiting period for Achillion(ACHN) acquisition by Alexion Pharmaceuticals (ALXN) for $930M
Tickers: ACHN, ALXN
Announcement Date: Jan 27, 2020
Alexion (ALXN) And Eidos' (EIDX) subsidiary - BridgeBio (BBIO) Agree On Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine License
Tickers: ALXN, EIDX, BBIO
Announcement Date: Sep 09, 2019
Alexion Pharmaceuticals (ALXN) has agreed to co-develop CP010, a C6 complement inhibitor for the potential treatment of neurodegenerative disorders, with Complement Pharma
Ticker: ALXN
Announcement Date: Jun 11, 2018
Alexion (ALXN) to acquire Wilson Therapeutics
Ticker: ALXN
Announcement Date: May 25, 2018

ALXN Overview